抗整合素αvβ6自身抗体在合并炎症性肠病的原发性硬化性胆管炎患者中升高并与肝病严重程度相关
研究纳入137例原发性硬化性胆管炎(PSC)患者和160例对照,检测抗整合素αvβ6自身抗体(anti-αvβ6)水平。合并炎症性肠病(IBD)的PSC患者anti-αvβ6显著高于单纯PSC患者和健康对照,且与碱性磷酸酶、修订版Mayo PSC风险评分及肝脏硬度相关。结论认为anti-αvβ6可识别合并IBD的PSC患者亚群。
要点
- 合并IBD的PSC患者anti-αvβ6水平显著高于单纯PSC患者和健康对照。
- 单纯PSC患者anti-αvβ6水平与健康对照相比未升高。
- 在PSC-IBD患者中,anti-αvβ6与碱性磷酸酶、修订版Mayo PSC风险评分及肝脏硬度相关。
核心结论
- 抗整合素αvβ6自身抗体可识别合并炎症性肠病的原发性硬化性胆管炎患者亚群。
研究设计与样本
- 研究纳入四个肝移植前PSC患者队列,以IBD患者和健康对照为比较对象,采用酶联免疫吸附试验测定总IgG和anti-αvβ6水平,并对部分样本运行Olink炎症panel,采用多变量线性回归分析anti-αvβ6与肝病严重程度指标的关联。
- 共纳入137例PSC患者(包括76例PSC-UC、33例PSC-CD和28例单纯PSC)和160例对照(包括91例IBD和69例健康对照)。
主要发现
- PSC-UC和PSC-CD患者的anti-αvβ6水平显著高于单纯PSC患者(P < .0001和P < .003)和健康对照(P < .0001和P < .0001)。
- 单纯PSC患者的anti-αvβ6水平与健康对照相比未升高。
- 在PSC-IBD患者中,校正年龄、性别、种族/民族和IBD亚型后,anti-αvβ6水平与碱性磷酸酶水平(r = 0.32;P = .004)、修订版Mayo PSC风险评分(r = 0.25;P = .02)和肝脏硬度测量(r = 0.43;P = .008)相关。
- anti-αvβ6水平与全身炎症和组织重塑标志物相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Anti-integrin αvβ6 autoantibodies (anti-αvβ6) are found in more than 50% of individuals with ulcerative colitis (UC). We aimed to determine the prevalence of anti-αvβ6 in patients with primary sclerosing cholangitis (PSC) and their association with liver disease severity. METHODS: Four cohorts of pre-liver transplant patients with PSC were recruited. Patients with inflammatory bowel disease (IBD) and healthy controls (HCs) served as comparators. Total IgG and anti-αvβ6 levels were measured using enzyme-linked immunosorbent assay. Olink inflammation panel was run on a subset of samples. Multivariable linear regression analysis was performed to assess the association between anti-αvβ6 and indices of liver disease severity. RESULTS: A total of 137 patients with PSC (including 76 with PSC-UC, 33 with PSC-Crohn's disease (CD), and 28 with PSC alone) and 160 controls (including 91 with IBD and 69 HCs) were enrolled. Anti-αvβ6 levels were significantly higher in PSC-UC and PSC-CD compared with PSC alone (P < .0001 and P < .003) and HCs (P < .0001 and P < .0001). However, anti-αvβ6 levels in PSC alone were not increased compared with HCs. In patients with PSC-IBD, anti-αvβ6 levels correlated with markers of liver disease severity, including alkaline phosphatase level (r = 0.32; P = .004), the revised Mayo PSC risk score (r = 0.25; P = .02), and liver stiffness measurement (r = 0.43; P = .008) after adjusting for age, gender, race/ethnicity, and IBD subtype. Additionally, anti-αvβ6 levels were associated with markers of systemic inflammation and tissue remodeling. CONCLUSION: Anti-αvβ6 autoantibodies identify a subset of patients with PSC with concomitant IBD.
引用
- Bloemen H, Livanos AE, Martins A, et al. Anti-integrin αvβ6 Autoantibodies Are Increased in Primary Sclerosing Cholangitis Patients With Concomitant Inflammatory Bowel Disease and Correlate With Liver Disease Severity. Clin Gastroenterol Hepatol. 2024. PMID: 39490950. doi:10.1016/j.cgh.2024.10.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。